白癜风生物标志物CXCL10与芦可替尼乳膏临床应答相关:2期随机TRuE-V机制研究
这项2期随机双盲溶媒对照试验纳入成人白癜风患者,按2:1随机接受每日两次1.5%芦可替尼乳膏(n=41)或溶媒(n=19)治疗24周,之后全部使用芦可替尼乳膏至第52周。结果显示芦可替尼乳膏显著下调血清IFN-γ相关蛋白(包括CXCL10),血清和皮损内CXCL10表达从基线至第12-40周显著降低,且CXCL10降低与T-VASI改善显著相关。结论确认IFN-γ-CXCL10轴在白癜风发病中的作用,提示CXCL10降低与芦可替尼乳膏临床复色相关。
要点
- 芦可替尼乳膏显著下调血清IFN-γ相关蛋白包括CXCL10(P<0.05)。
- 血清和皮损CXCL10表达第12-40周较基线显著降低(P<0.05)。
- CXCL10降低与T-VASI改善显著相关(P<0.05/P<0.001)。
核心结论
- 数据确认IFN-γ-CXCL10轴在白癜风发病中起作用。
- CXCL10表达降低与芦可替尼乳膏临床复色相关。
研究设计与样本
- 2期随机双盲溶媒对照试验,成人白癜风患者随机2:1接受每日两次1.5%芦可替尼乳膏(n=41)或溶媒(n=19)治疗24周,之后全部使用芦可替尼乳膏至第52周。
主要发现
- 芦可替尼乳膏在所有治疗后时间点显著下调血清IFN-γ相关蛋白包括CXCL10(P<0.05;倍数变化>1.25)。
- 血清和皮损内CXCL10表达从基线至第12-40周显著降低(P<0.05)。
- 芦可替尼乳膏组F-VASI从基线平均降低百分比在第12周为-32.9%(P<0.01)、第24周为-49.1%(P<0.001);T-VASI第24周为-21.2%(P<0.05)。
- 血清和皮损CXCL10表达降低与T-VASI改善显著相关(P<0.05/P<0.001)。
- 芦可替尼乳膏治疗24周后SOX10+黑素细胞计数增加与F-VASI改善显著相关(P<0.05)。
关键数值与推荐
- 芦可替尼乳膏1.5%每日两次外用。
- F-VASI第12周降低32.9%(P<0.01),第24周降低49.1%(P<0.001)。
- T-VASI第24周降低21.2%(P<0.05)。
临床怎么用
- CXCL10可作为白癜风疾病活动性和治疗应答的潜在生物标志物。
- 芦可替尼乳膏通过抑制IFN-γ-CXCL10轴促进复色。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TRIAL DESIGN: This phase 2, randomized, double-blind, vehicle-controlled trial investigated the mechanism of action of ruxolitinib cream in vitiligo. METHODS: Adults with vitiligo were randomized 2:1 to twice-daily 1.5% ruxolitinib cream (n=41) or vehicle (n=19) for 24 weeks, after which they applied twice-daily ruxolitinib cream through Week 52. RESULTS: Analyses showed significant downregulation of serum proteins related to interferon-gamma (IFN-γ), including IFN-γ-inducible C-X-C motif chemokine ligand 10 (CXCL10) at all post-ruxolitinib cream time points (P<0.05; fold change >1.25). In sera and lesional skin, CXCL10 expression was significantly reduced from baseline at Weeks 12 through 40 (P<0.05). Among patients applying ruxolitinib cream, mean percentage reductions from baseline were significant at Weeks 12 and 24 for facial Vitiligo Area Scoring Index (F-VASI: -32.9%; P<0.01/-49.1%; P<0.001) and Week 24 for total VASI (T-VASI; -21.2%; P<0.05). Reduced CXCL10 expression in sera and lesional skin significantly correlated with T-VASI improvement (P<0.05/P<0.001). Additionally, following 24 weeks of ruxolitinib cream treatment, increases in SOX10+ melanocyte counts significantly correlated with F-VASI improvements (P<0.05). CONCLUSIONS: These data confirm a role for the IFN-γ-CXCL10 axis in vitiligo pathogenesis and suggest that reductions in CXCL10 expression correlate with clinical repigmentation with ruxolitinib cream (clinicaltrials.gov: NCT04896385).
引用
- Passeron T, Lebwohl M, Lynde C, et al. Vitiligo Biomarker CXCL10 Correlates With Clinical Response to Ruxolitinib Cream in the Phase 2 Randomized TRuE-V Mechanism-of-Action Study. J Invest Dermatol. 2026. PMID: 42869214. doi:10.1016/j.jid.2026.09.857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。